BIOCELL2025，Vol.49Issue(4)：P.539-562,24.DOI:10.32604/biocell.2025.059970
Evaluating Oncogenic Drivers and Therapeutic Potential of the PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma: An Overview of Clinical Trials
Ayda Baghery Saghchy Khorasani 1Mahda Delshad 2Mohammad-Javad Sanaei 3Atieh Pourbagheri-Sigaroodi 2Ali Pirsalehi 4Davood Bashash2
作者信息
- 1. Department of Hematology,School of Medical Sciences,Tarbiat Modares University,Tehran,1411713116,Iran
- 2. Department of Hematology and Blood Banking,School of Allied Medical Sciences,Shahid Beheshti University of Medical Sciences,Tehran,1971653313,Iran
- 3. Department of Hematology and Blood Banking,School of Allied Medical Sciences,Shahid Beheshti University of Medical Sciences,Tehran,1971653313,Iran Gastroenterology and Liver Diseases Research Center,Research Institute for Gastroenterology and Liver Diseases,Shahid Beheshti University of Medical Sciences,Tehran,1985714711,Iran
- 4. Department of Internal Medicine,School of Medicine,Shahid Beheshti University of Medical Sciences,Tehran,1985717443,Iran
- 折叠
摘要
关键词
HCC/PI3K/AKT/mTOR/clinicaltrial分类
医药卫生引用本文复制引用
Ayda Baghery Saghchy Khorasani,Mahda Delshad,Mohammad-Javad Sanaei,Atieh Pourbagheri-Sigaroodi,Ali Pirsalehi,Davood Bashash..Evaluating Oncogenic Drivers and Therapeutic Potential of the PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma: An Overview of Clinical Trials[J].BIOCELL,2025,49(4):P.539-562,24.
